Ergot mesylates for alzheimer's disease: A year-long double-blind trial of 3 mg vs 12 mg daily

1990 ◽  
Vol 5 (6) ◽  
pp. 375-380 ◽  
Author(s):  
Michael A. Jenike ◽  
Marilyn Albert ◽  
Lee Baer ◽  
Jeanette Gunther ◽  
Christine Corvino
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial

Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial

2009 ◽  
Vol 8 (1) ◽  
pp. 39-47 ◽  
Author(s):  
Alistair Burns ◽  
Roberto Bernabei ◽  
Roger Bullock ◽  
Alfonso J Cruz Jentoft ◽  
Lutz Frölich ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Double Blind Trial ◽  
Double Blind ◽  
Safety And Efficacy ◽  
Blind Trial

Double Blind Study of Lecithin in Patients with Alzheimer's Disease

1981 ◽  
Vol 26 (6) ◽  
pp. 426-428 ◽  
Author(s):  
M. Fisman ◽  
H. Merskey ◽  
E. Helmes ◽  
J. Mccready ◽  
E.H. Colhoun ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Serum Levels ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial

Twenty-one patients with a diagnosis of Alzheimer's disease completed a double blind trial on lecithin 25 g daily. Equal improvement was noted in both the lecithin and placebo groups. Serum levels of lecithin measured 12-14 hours after its administration were also not increased compared with the levels in control patients. These findings of the ineffectiveness of lecithin inpatients with Alzheimer's disease are discussed in relation to the literature on this subject.

Sign in / Sign up

Export Citation Format

Share Document